RA
GNOM icon

Rise Advisors’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Rise Advisors’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-125
Closed -$5.63K – 1156
2024
Q3 		$5.63K Hold
125
– – ﹤0.01% 1072
2024
Q2 		$5.22K Hold
125
– – ﹤0.01% 1073
2024
Q1 		$5.69K Hold
125
– – ﹤0.01% 1084
2023
Q4 		$5.78K Hold
125
– – ﹤0.01% 368
2023
Q3 		$5.08K Hold
125
– – ﹤0.01% 376
2023
Q2 		$6.06K Buy
+125
New +$6.25K ﹤0.01% 401

Other funds holding GNOM

OCM
One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
Mirae Asset Global ETFs Holdings
Mirae Asset Global ETFs Holdings Causeway Bay, Hong Kong $73.7B AUM 53.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.11B AUM 20.67% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Rise Advisors's GNOM Position: Q4 2024 in Review

Rise Advisors sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q4 2024, closing a stake of 125 shares — an estimated $5.63K sold.

Rise Advisors first reported a position in GNOM in Q2 2023 and held it in 6 quarters. The position peaked at $6.06K in Q2 2023. 68 funds tracked by Wall St. Rank hold GNOM as of Q4 2024.

  • Rise Advisors reported no remaining Global X Genomics & Biotechnology ETF position as of Q4 2024 after selling out during the quarter.
  • Rise Advisors sold 125 Global X Genomics & Biotechnology ETF shares in Q4 2024, an estimated $5.63K.
  • Rise Advisors first reported a position in Global X Genomics & Biotechnology ETF in Q2 2023 and held it in 6 quarters.
  • Rise Advisors's Global X Genomics & Biotechnology ETF position peaked at $6.06K in Q2 2023.
  • 68 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q4 2024.

Based on Rise Advisors's 13F filing for Q4 2024, filed 7 Jan 2025.